The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients? Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of patients who had acute coronary syndrome
Timeframe: From start of the study to 3 months after